When the structure of VEGFR inhibitors is examined, it is seen that it consists of 4 pharmacophoric parts. In the light of this information, within the scope of this study, new 2‐((1‐(4‐(1H‐imidazol‐1‐yl)phenyl)ethylidene)hydrazineylidene)‐3‐ethyl‐4‐(substitutephenyl)‐2,3‐dihydrothiazole derivatives were synthesized. Structure determinations of the synthesized derivatives were made using spectroscopic methods. Firstly, the resulting compounds (4a‐4l) were subjected to the 24‐hour MTT test against MCF7, HepG2 and NIH3T3 cells. According to the MTT test results, compound 4h showed activity with IC50=4.566±0.246 µM and compound 4k with IC50=4.537±0.463 µM against HepG2 cell line. The antifungal activities and biofilm inhibition percentages of all compounds against infection problems that may develop in patients receiving chemotherapy were investigated. Compounds 4h and 4k which are active in the MTT test were tested for inhibition of VEGFR‐2 enzymes. Compound 4h displayed VEGFR‐2 inhibition with IC50=0.066±0.002 µM value; compound 4k did not show enzyme inhibition with an IC50>10 µM. Molecular docking studies were performed with two compounds (4k and 4h) and sorafenib to understand the dramatic difference for VEGFR‐2 inhibition. Molecular dynamics studies were performed with using 4h‐4ASE complex and both stability (RMSD, RMSF, Rg) and interaction potentials of the complex were analyzed and presented.